No products
View larger AOB8379
1948 Items
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $8.50 | Total: $42.50 |
| 1 | 10 | $7.20 | Total: $72.00 |
| 1 | 25 | $6.10 | Total: $152.50 |
| 1 | 50 | $5.20 | Total: $260.00 |
| 1 | 100 | $4.50 | Total: $450.00 |
| Molecular Formula | C29H37N7O5S |
| Molecular Weight | 595.72 |
| CAS Numbers | 1421373-66-1 (mesylate) |
| Storage Condition | 0°C (short term), -20°C (long term), desiccated |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| Synonym | AZD-9291; AZD 9291; AZD9291; AZD-9291 mesylate; Mereletinib; Mereletinib mesylate; Osimertinib mesylate. Brand name: Tagrisso. |
| IUPAC/Chemical Name | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide mesylate |
| InChl Key | FUKSNUHSJBTCFJ-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4) |
| SMILES Code | CN(CCN(C)C)C1=CC(OC)=C(C=C1NC(C=C)=O)NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2.OS(=O)(C)=O |
| References | 1) Zhang Z, Yang S, Wang Q. Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomark Res. 2019 Nov 21;7:27. doi: 10.1186/s40364-019-0179-6. eCollection 2019. Review. PubMed PMID: 31832192; PubMed Central PMCID: PMC6873421. 2) Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Indian J Cancer. 2019 Nov;56(Supplement):S31-S37. doi: 10.4103/ijc.IJC_455_19. Review. PubMed PMID: 31793440. |